Daewon Pharmaceutical is restructuring its cosmetics business by hiring a dermocosmetics expert. This appointment is seen as part of efforts to improve the company's subsidiary operations.
On June 16, Daewon Pharmaceutical announced the appointment of Kim Hye-won, former executive director at CMS Lab, as the new CEO of its subsidiary, SD BioPharm.
Kim brings 26 years of experience in the beauty industry, having held various roles in planning, marketing, sales, and as a research director at major domestic companies such as Amorepacific, Neopharm, and CMS Lab. The company plans to revamp its brand portfolio and strengthen its domestic and international distribution capabilities to accelerate growth in the cosmetics sector.
SD BioPharm was acquired to diversify its business across pharmaceuticals, health supplements, and cosmetics. However, it has faced financial challenges, recording operating losses of 9.2 billion won in 2024 and 6.3 billion won last year.
Kim stated, "We will systematize the business structure through a multifaceted assessment of current distribution channels and a product-centered sales and marketing strategy. I will focus on building a sustainable growth pipeline for SD BioPharm based on my extensive ODM network and experience in designing new business cycles."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.